AVTX SEC Form 4 filings
Avalo Therapeutics, Inc. Latest Insider Trading Activity
Over the past 75 days, 10 insider trades from Avalo Therapeutics, Inc. (AVTX). The most recent SEC Form 4 filing shows a sale by Doyle Mittie (Avalo Therapeutics, Inc. Chief Medical Officer) on August 28, 2026 involving 679 shares at $20.00 per share. This page shows up to the 10 most recent SEC Form 4 filing records on a 24-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.
⚠️ THE SAMPLE BELOW IS DEFERRED BY 24 HOURS ⚠️
Start your 2-week, no-credit-card free trial today to receive get down to the second insider trading updates in this directory or email.
| Ticker | Filing Date | Transaction Date | Company | Insider | Title | Transaction | Trade Count | Shares | Avg. Price | Total Value | Position Size Change | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AVTX | 2026-09-01 | 2026-08-28 | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 1 | 679 | $20.00 | $13,580.00 | 1.29% | View Filing |
| AVTX | 2026-08-19 | 2026-08-17 | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 1 | 1,000 | $20.00 | $20,000.00 | 1.89% | View Filing |
| AVTX | 2026-08-19 | 2026-08-17 | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 1 | 3,749 | $19.94 | $74,762.18 | 8.59% | View Filing |
| AVTX | 2026-08-19 | 2026-08-17 | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 1 | 37,945 | $19.85 | $753,333.47 | 46.50% | View Filing |
| AVTX | 2026-08-19 | 2026-08-18 | Avalo Therapeutics, Inc. | Sullivan Christopher Ryan | Chief Financial Officer | Sell | 1 | 31,031 | $20.05 | $622,323.60 | 43.75% | View Filing |
| AVTX | 2026-08-12 | 2026-08-11 | Avalo Therapeutics, Inc. | Riley Jennifer | Chief Strategy Officer | Sell | 1 | 2,655 | $19.59 | $52,012.25 | 6.69% | View Filing |
| AVTX | 2026-08-12 | 2026-08-10 | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 1 | 679 | $20.00 | $13,580.00 | 1.29% | View Filing |
| AVTX | 2026-07-29 | 2026-07-27 | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 1 | 1,000 | $20.00 | $20,000.00 | 1.89% | View Filing |
| AVTX | 2026-07-02 | 2026-06-30 | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 1 | 4,654 | $20.00 | $93,080.00 | 8.25% | View Filing |
| AVTX | 2026-06-25 | 2026-06-23 | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | Sell | 1 | 1,450 | $18.00 | $26,100.00 | 2.72% | View Filing |
Real-time employee trading alerts from SEC Form 4 filings. Sign up for a free trial. No credit card required.
Pricing
Free Trial
10 trading days$0
Explore every Premium feature before you pay.
- Full platform access
- 10 trading days
- No credit card required
- 20 years of alert history
- Live alert directory updates
Standard Monthly
Scheduled$19.99 / month
Scheduled alerts with complete trade context.
- Email and Telegram delivery
- Alert intervals from every sixty minutes to once daily
- Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
- Highlighted cluster transactions and SEC filing links
- Access to the alert directory hourly refreshes
Premium Monthly
Recommended$29.99 / month
Fastest alerts with ticker-level control.
- Everything in Standard
- Instant delivery detection-to-outbound time averages 0.85 seconds
- Alert intervals starting from one minute
- Real time alert directory updates
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.